Condition (MeSH)
Sialorrhea
ClinicalTrials.gov lists 56 trials for Sialorrhea or a narrower condition beneath it. Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
56 of the 56 trials are tagged with Sialorrhea itself; the rest are tagged with a narrower condition beneath it.
When did Sialorrhea trials start? (24)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 7
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 3 |
| 2024 | 3 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 7 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 24 earlier years.
No forecast is made for this condition: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Sialorrhea trials in? (8)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 4 |
| Phase 1/2 | 1 |
| Phase 2 | 10 |
| Phase 2/3 | 3 |
| Phase 3 | 4 |
| Phase 4 | 3 |
| Not applicable | 20 |
| Observational | 11 |
How many Sialorrhea trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 2 |
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 34 |
| Withdrawn | 3 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Sialorrhea trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC | 3 |
| NeuroHealing Pharmaceuticals Inc. | 2 |
| Azur Pharma, Inc | 1 |
Which drugs are being tested for Sialorrhea? (1)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| BOTULINUM TOXIN TYPE B | 4 |
Interventions as named in the registry (14)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| glycopyrrolate, 2.0% | 4 |
| Atropine 1% | 2 |
| DRibble Vaccine | 2 |
| Ipratropium HFA | 2 |
| type A botulinum toxin | 2 |
Showing 5 of 14 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Sialorrhea trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 15 | 3 |
| Amyotrophic lateral sclerosis | 9 | 2 |
| Neoplasm progression | 6 | 1 |
| Pneumonia aspiration | 5 | 3 |
| Respiratory failure | 5 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Sialorrhea? (60)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Mid-long term efficacy of dihydroergotoxine mesylate in treatment of sialorrhea in Parkinson's disease. | Clinical neurology and neurosurgery | 2026 | Yes |
| Deep brain stimulation of the subthalamic nucleus increases the risk of sialorrhea in patients with advanced Parkinson's disease. | Parkinsonism & related disorders | 2024 | Yes |
| Button Battery Ingestion in Children (PilBouTox®): A Prospective Study Describing the Clinical Course and Identifying Factors Related to Esophageal Impaction or Severe Cases. | Dysphagia | 2023 | Yes |
| Prevalence of clozapine-induced sialorrhea and its effect on quality of life. | Psychopharmacology | 2023 | Yes |
| Orofacial function and temporomandibular disorders in Parkinson's Disease: a case-controlled study. | BMC oral health | 2023 | Yes |
Showing 5 of 60 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.